Apomorphine for Parkinson’s disease: pharmacologic and clinical considerations

References

• Reich SG, Savitt JM. Parkinson’s Disease. Med Clin North Am. 2019;103(2):337–350. doi: 10.1016/j.mcna.2018.10.014
   PubMed Web of Science ®Google Scholar
• de Rijk MC, Breteler MM, Graveland GA, et al. Prevalence of Parkinson’s disease in the elderly: the Rotterdam study. Neurology. 1995;45:2143–2146. doi: 10.1212/WNL.45.12.2143
   PubMed Web of Science ®Google Scholar
• Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427–442. doi: 10.1212/WNL.17.5.427
   PubMed Web of Science ®Google Scholar
• Obeso JA, Rodríguez-Oroz MC, Rodríguez M, et al. Pathophysiology of the basal ganglia in Parkinson’s disease. Trends Neurosci. 2000;23:S8–19. doi: 10.1016/S1471-1931(00)00028-8
   PubMed Web of Science ®Google Scholar
• Marsden CD, Parkes JD. “ON-OFF” EFFECTS IN PATIENTS WITH PARKINSON’S DISEASE ON CHRONIC LEVODOPA THERAPY. Lancet. 1976;307(7954):292–296. doi: 10.1016/S0140-6736(76)91416-1
   Google Scholar
• Armstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020;323(6):548–560. doi: 10.1001/jama.2019.22360
   PubMed Web of Science ®Google Scholar
• Chou KL, Stacy M, Simuni T, et al. The spectrum of “off” in Parkinson’s disease: what have we learned over 40 years? Parkinsonism Relat Disord. 2018;51:9–16. doi: 10.1016/j.parkreldis.2018.02.001
   PubMed Web of Science ®Google Scholar
• Carbone F, Djamshidian A, Seppi K, et al. Apomorphine for Parkinson’s disease: efficacy and safety of Current and new formulations. CNS Drugs. 2019;33(9):905–918. doi: 10.1007/s40263-019-00661-z
   PubMed Web of Science ®Google Scholar
• Auffret M, Drapier S, Vérin M. The many faces of apomorphine: lessons from the past and challenges for the future. Drugs RD. 2018;18:91–107.
   PubMed Web of Science ®Google Scholar
• Schwab RS, Amador LV, Lettvin JY. Apomorphine in Parkinson’s disease. Trans Am Neurol Assoc. 1951;56:251–253.
   PubMedGoogle Scholar
• Kempster PA, Frankel JP, Stern GM, et al. Comparison of motor response to apomorphine and levodopa in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1990;53(11):1004–1007. doi: 10.1136/jnnp.53.11.1004
   PubMed Web of Science ®Google Scholar
• Richard B DJ, Hutton JT, LeWitt PA, et al. A randomized, Double-blind, placebo-controlled trial of subcutaneously injected apomorphine for Parkinsonian off-state events. Arch Neurol. 2001;58:1385–1392. doi: 10.1001/archneur.58.9.1385
   PubMedGoogle Scholar
• Pahwa R, Pagan FL, Kremens DE, et al. Clinical use of on-demand therapies for patients with Parkinson’s disease and off periods. Neurol Ther. 2023;12(4):1033–1049. doi: 10.1007/s40120-023-00486-5
   PubMed Web of Science ®Google Scholar
• Apomorphine subcutaneous injection for the management of morning akinesia in Parkinson’s disease - Isaacson - 2017 - movement disorders clinical practice - Wiley online library [Internet]. [cited 2023 Mar 8]. Available from: https://movementdisorders.onlinelibrary.wiley.com/doi/full/10.1002/mdc3.12350.
   Google Scholar
• Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386:896–912. doi: 10.1016/S0140-6736(14)61393-3
   PubMed Web of Science ®Google Scholar
• Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79:368–376. doi: 10.1136/jnnp.2007.131045
   PubMed Web of Science ®Google Scholar
• Shadrina M, Slominsky P. Modeling Parkinson’s disease: not only rodents? Front Aging Neurosci. 2021;13:695718. doi: 10.3389/fnagi.2021.695718
   PubMedGoogle Scholar
• Othman AA, Dutta S. Population pharmacokinetics of levodopa in subjects with advanced Parkinson’s disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. Br J Clin Pharmacol. 2014;78:94–105. doi: 10.1111/bcp.12324
   PubMed Web of Science ®Google Scholar
• Poewe W, Bergmann L, Kukreja P, et al. Levodopa-carbidopa intestinal gel monotherapy: GLORIA registry demographics, efficacy, and safety. J Park Dis. 2019;9(3):531–541. doi: 10.3233/JPD-191605
   Web of Science ®Google Scholar
• Martinez-Nunez AE, LeWitt PA. Drugs to the rescue: comparison of on-demand therapies for off symptoms in Parkinson’s disease. J Park Dis. 2023;13(4):441–451. doi: 10.3233/JPD-230055
   Web of Science ®Google Scholar
• Rosa-Grilo M, Qamar MA, Evans A, et al. The efficacy of apomorphine - a non-motor perspective. Parkinsonism Relat Disord. 2016;33(Suppl 1):S28–S35. doi: 10.1016/j.parkreldis.2016.11.020
   PubMedGoogle Scholar
• Yarnall AJ, Lashley T, Ling H, et al. Apomorphine: a potential modifier of amyloid deposition in Parkinson’s disease? Mov Disord Off J Mov Disord Soc. 2016;31(5):668–675. doi: 10.1002/mds.26422
   PubMed Web of Science ®Google Scholar
• Lim EW, Aarsland D, Ffytche D, et al. Amyloid-β and Parkinson’s disease. J Neurol. 2019;266(11):2605–2619. doi: 10.1007/s00415-018-9100-8
   PubMed Web of Science ®Google Scholar
• Factor SA. DOPAMINE AGONISTS. Med Clin North Am. 1999;83(2):415–443. doi: 10.1016/S0025-7125(05)70112-7
   PubMed Web of Science ®Google Scholar
• Ribarič S. The pharmacological properties and therapeutic use of apomorphine. Molecules. 2012;17(5):5289–5309. doi: 10.3390/molecules17055289
   PubMed Web of Science ®Google Scholar
• Bhidayasiri R, Chaudhuri KR, LeWitt P, et al. Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses. Clin Neuropharmacol. 2015;38(3):89–103. doi: 10.1097/WNF.0000000000000082
   PubMed Web of Science ®Google Scholar
• Jenner P, Katzenschlager R. Apomorphine - pharmacological properties and clinical trials in Parkinson’s disease. Parkinsonism Relat Disord. 2016;33:S13–S21. doi: 10.1016/j.parkreldis.2016.12.003
   PubMed Web of Science ®Google Scholar
• Auffret M, Drapier S, Vérin M. New tricks for an old dog: a repurposing approach of apomorphine. Eur J Pharmacol. 2019;843:66–79. doi: 10.1016/j.ejphar.2018.10.052
   PubMed Web of Science ®Google Scholar
• Przedborski S, Levivier M, Raftopoulos C, et al. Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans. Mov Disord Off J Mov Disord Soc. 1995;10(1):28–36. doi: 10.1002/mds.870100107
   PubMed Web of Science ®Google Scholar
• Fung VSC, Hely MA, Morris JGL. Drugs for Parkinson’s disease. 2001;24. doi: 10.18773/austprescr.2001.099
   Google Scholar
• Millan MJ, Maiofiss L, Cussac D, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002;303(2):791–804. doi: 10.1124/jpet.102.039867
   PubMed Web of Science ®Google Scholar
• Jaber M, Robinson SW, Missale C, et al. Dopamine receptors and brain function. Neuropharmacology. 1996;35(11):1503–1519. doi: 10.1016/S0028-3908(96)00100-1
   PubMed Web of Science ®Google Scholar
• Stacy M, Silver D. Apomorphine for the acute treatment of “off” episodes in Parkinson’s disease. Parkinsonism Relat Disord. 2008;14(2):85–92. doi: 10.1016/j.parkreldis.2007.07.016
   PubMed Web of Science ®Google Scholar
• Boyle A, Ondo W. Role of apomorphine in the treatment of Parkinson’s disease. CNS Drugs. 2015;29(2):83–89. doi: 10.1007/s40263-014-0221-z
   PubMed Web of Science ®Google Scholar
• Nomoto M, Kubo S, Nagai M, et al. A randomized controlled trial of subcutaneous apomorphine for Parkinson disease: a repeat dose and pharmacokinetic study. Clin Neuropharmacol. 2015;38(6):241. doi: 10.1097/WNF.0000000000000111
   PubMed Web of Science ®Google Scholar
• Agbo F, Isaacson SH, Gil R, et al. Pharmacokinetics and comparative bioavailability of apomorphine sublingual Film and subcutaneous apomorphine formulations in patients with Parkinson’s disease and “OFF” episodes: results of a randomized, three-way crossover, open-label study. Neurol Ther. 2021;10(2):693–709. doi: 10.1007/s40120-021-00251-6
   PubMed Web of Science ®Google Scholar
• LeWitt PA. Subcutaneously administered apomorphine: pharmacokinetics and metabolism. Neurology. 2004;62(Issue 6, Supplement 4):S8–S11. doi: 10.1212/WNL.62.6_suppl_4.S8
   PubMed Web of Science ®Google Scholar
• van der Geest R, van Laar T, Kruger PP, et al. Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson’s disease. Clin Neuropharmacol. 1998;21:159–168.
   PubMed Web of Science ®Google Scholar
• Gancher ST, Woodward WR, Boucher B, et al. Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol. 1989;26(2):232–238. doi: 10.1002/ana.410260209
   PubMed Web of Science ®Google Scholar
• Parkinson’s disease treatment market size global report, 2022 - 2030 [Internet]. Polaris. [cited 2023 Aug 11]. Available from: https://www.polarismarketresearch.com/index.php/industry-analysis/global-parkinsons-disease-treatment-market
   Google Scholar
• LeWitt PA, Ondo WG, Van Lunen B, et al. Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating “off” episodes in advanced Parkinson disease. Clin Neuropharmacol. 2009;32(2):89. doi: 10.1097/WNF.0b013e31816d91f9
   PubMed Web of Science ®Google Scholar
• Katzenschlager R, Poewe W, Rascol O, et al. Long-term safety and efficacy of apomorphine infusion in Parkinson’s disease patients with persistent motor fluctuations: results of the open-label phase of the TOLEDO study. Parkinsonism Relat Disord. 2021;83:79–85. doi: 10.1016/j.parkreldis.2020.12.024
   PubMed Web of Science ®Google Scholar
• Deleu D, Hanssens Y, Northway MG. Subcutaneous apomorphine: an evidence-based review of its use in Parkinson’s disease. Drugs Aging. 2004;21(11):687–709. doi: 10.2165/00002512-200421110-00001
   PubMed Web of Science ®Google Scholar
• Hagell P, Höglund A, Hellqvist C, et al. Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson’s disease. J Neurol. 2020;267(11):3411–3417. doi: 10.1007/s00415-020-10031-1
   PubMed Web of Science ®Google Scholar
• Pfeiffer RF, Gutmann L, Hull KL, et al. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson’s disease. Parkinsonism Relat Disord. 2007;13(2):93–100. doi: 10.1016/j.parkreldis.2006.06.012
   PubMed Web of Science ®Google Scholar
• Isaacson S, Lew M, Ondo W, et al. Apomorphine subcutaneous injection for the management of morning akinesia in Parkinson’s disease. Mov Disord Clin Pract. 2017;4(1):78–83. doi: 10.1002/mdc3.12350
   PubMed Web of Science ®Google Scholar
• Belkacemi L, Darmani NA. Dopamine receptors in emesis: molecular mechanisms and potential therapeutic function. Pharmacol Res. 2020;161:105124. doi: 10.1016/j.phrs.2020.105124
   PubMed Web of Science ®Google Scholar
• Olivola E, Fasano A, Varanese S, et al. Continuous subcutaneous apomorphine infusion in Parkinson’s disease: causes of discontinuation and subsequent treatment strategies. Neurol Sci. 2019;40:1917–1923.
   PubMed Web of Science ®Google Scholar
• Antonini A, Odin P, Pahwa R, et al. The long-term impact of levodopa/carbidopa intestinal gel on ‘off’-time in patients with advanced Parkinson’s disease: a systematic review. Adv Ther. 2021;38(6):2854–2890. doi: 10.1007/s12325-021-01747-1
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Hauser RA, Pahwa R, et al. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2019;18(2):145–154. doi: 10.1016/S1474-4422(18)30405-8
   PubMed Web of Science ®Google Scholar
• Berger AA, Winnick A, Welschmeyer A, et al. Istradefylline to treat patients with Parkinson’s disease experiencing “off” episodes: a comprehensive review. Neurol Int. 2020;12:109–129. doi: 10.3390/neurolint12030017
   PubMed Web of Science ®Google Scholar
• Thijssen E, den Heijer J, Puibert D, et al. A randomized trial assessing the safety, pharmacokinetics, and efficacy during morning off of AZ‐009. Mov Disord. 2022;37:790–798. doi: 10.1002/mds.28926
   PubMed Web of Science ®Google Scholar
• Thach A, Kirson N, Zichlin ML, et al. Cost-effectiveness of apomorphine sublingual Film as an “on-demand” treatment for “OFF” episodes in patients with Parkinson’s disease. J Health Econ Outcomes Res. 2021;8(2):82–92. doi: 10.36469/jheor.2021.29488
   PubMedGoogle Scholar
• Olanow CW, Factor SA, Espay AJ, et al. Apomorphine sublingual film for off episodes in Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurol. 2020;19(2):135–144. doi: 10.1016/S1474-4422(19)30396-5
   PubMed Web of Science ®Google Scholar
• Sunovion crowds a new group of Parkinson’s drugs, with uncertain sales prospects [Internet]. BioPharma Dive. [cited 2023 Aug 9]. Available from: https://www.biopharmadive.com/news/parkinsons-drugs-sunovion-fda-approval/578514/.
   Google Scholar
• How to prescribe INBRIJA® (levodopa inhalation powder) [Internet]. HttpsWWWINBRIJA-HCPcom. [cited 2023 Oct 25]. Available from: https://www.INBRIJA-HCP.com/how-to-prescribe
   Google Scholar
• NOURIANZTM (istradefylline) | official healthcare professional site [Internet]. [cited 2023 Oct 25]. Available from: https://www.nourianzhcp.com/www.nourianzhcp.com.
   Google Scholar
• Parkinson’s Disease & DUOPATM (carbidopa/levodopa) | Official Patient Site [Internet]. [cited 2023 Oct 25]. Available from: https://www.duopa.com/.
   Google Scholar
• APOKYN® for Parkinson’s Disease Off Episodes [Internet]. [cited 2023 Oct 25]. Available from: https://www.apokyn.com/.
   Google Scholar
• ONGENTYS® (opicapone) capsules | patient & care partner site [Internet]. [cited 2023 Oct 25]. Available from: https://www.ongentys.com/
   Google Scholar
• Sunovion Announces US FDA approval of KYNMOBITM (apomorphine hydrochloride) sublingual Film for the treatment of Parkinson’s disease off episodes [Internet]. [cited 2023 Oct 25]. Available from: https://news.sunovion.com/press-releases/press-releases-details/2020/Sunovion-Announces-US-FDA-Approval-of-KYNMOBI-apomorphine-hydrochloride-Sublingual-Film-for-the-Treatment-of-Parkinsons-Disease-OFF-Episodes/default.aspx
   Google Scholar